Overview

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Status:
Completed
Trial end date:
2009-05-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig Institute for Cancer Research
Collaborator:
Memorial Sloan Kettering Cancer Center
Treatments:
Antibodies
Cadexomer iodine
Iodine